Cingulate Inc Stock Price, News & Analysis

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present an overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, from 3:00-3:30 p.m. ET in Miami, FL. The presentation will feature insights from CEO Shane J. Schaffer and CMO Matthew Brams, M.D. Interested investors can access the live webcast and later view a replay on Cingulate’s investor website for 90 days. The company focuses on its proprietary Precision Timed Release™ (PTR™) technology, primarily targeting ADHD treatment while exploring other therapeutic areas like anxiety disorders.

Cingulate Inc. (NASDAQ: CING) announced its financial results for Q1 2022 and dosed the first subject in a human formulation study of CTx-2103 for anxiety. The company aims to provide a single-dose therapeutic solution due to current treatment limitations. CTx-2103 could capture a segment of the U.S. anxiety market, valued over $5.5 billion. Cingulate reported a net loss of $5 million for the quarter and incurred R&D expenses of $2.8 million, reflecting an increase due to clinical activities. Cingulate seeks $21.5 million in additional capital to advance its projects.

Cingulate Inc. (NASDAQ: CING) presented a company overview at NobleCon18, highlighting its proprietary Precision Timed Release™ (PTR™) drug delivery platform. CEO Shane J. Schaffer detailed the company's focus on developing next-generation pharmaceuticals, particularly for Attention Deficit/Hyperactivity Disorder (ADHD). The presentation is available to view on the company’s website and will be archived for 90 days. Cingulate aims to improve treatment outcomes for patients with burdensome dosing regimens, with potential future applications in anxiety disorders.

Cingulate Inc. has successfully completed its Initial Public Offering, raising gross proceeds of $25 million. This funding aims to advance its lead investigational drug, CTx-1301, for treating ADHD, with plans to file a New Drug Application with the FDA in late 2023. The company has updated its clinical program to streamline research, potentially reducing costs and approval time. As of December 31, 2021, cash reserves stood at $16.5 million, enabling funding through late 2022.

KANSAS CITY, Kan., Feb. 15, 2022 – Cingulate Inc. (NASDAQ: CING) has announced that CEO Shane J. Schaffer will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET. Cingulate's presentation will be available for viewing from February 23 to February 25. The clinical-stage biopharmaceutical company focuses on its Precision Timed Release™ (PTR™) drug delivery technology to develop products addressing ADHD and other conditions. A webcast of the presentation will be available for 30 days after the event on Cingulate’s website.

Cingulate Inc. (NASDAQ: CING) has announced an expedited 2022 clinical program for its lead candidate, CTx-1301, aimed at treating ADHD. The company plans to initiate Phase 3 studies, including pediatric safety and efficacy assessments, in the second quarter of 2022. This acceleration, based on FDA feedback, is expected to lower capital requirements and expedite the New Drug Application filing anticipated in the latter half of 2023. Cingulate aims to enhance patient outcomes through its proprietary Precision Timed Release technology.

Cingulate Inc., a clinical-stage biopharmaceutical company, announced the appointment of Curt Medeiros and Gregg Givens to its Board of Directors following its IPO. Medeiros brings expertise in healthcare growth and market access, while Givens has over 35 years of finance experience. Both will contribute to the company’s vision of enhancing ADHD treatment and addressing unmet patient needs. Their backgrounds aim to strengthen Cingulate's leadership and business strategy as it advances its product pipeline, particularly targeting behavioral health and ADHD management.

Cingulate Inc. completed a $25 million Initial Public Offering (IPO) of Common Stock, facilitated by Aegis Capital Corp. as the Lead Bookrunning Manager. The company is focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) technology, particularly for treating Attention Deficit/Hyperactivity Disorder (ADHD). Their products aim to offer improved treatment outcomes and daily dosing regimens. Cingulate's pipeline includes innovative formulations like CTx-1301 and CTx-1302, designed for rapid onset and extended efficacy.

Cingulate Inc. has successfully completed its initial public offering, selling 4,166,666 shares of common stock along with warrants, generating approximately $25 million in gross proceeds. The shares and warrants now trade on the Nasdaq under the symbols ‘CING’ and ‘CINGW’, respectively. The funds will primarily support research and development for their product candidates, including CTx-1301 and CTx-1302, and cover various financial obligations. An over-allotment option was partially exercised, allowing for the sale of additional shares and warrants.